SLAMF7 Human

SLAMF7, also known as CD319, CRACC, and CS-1, is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors. These receptors play a crucial role in modulating the function of immune cells through immune-receptor tyrosine-based switch motifs and intracellular adaptor proteins .

SLAMF7 is a protein-coding gene that is expressed on the surface of various immune cells, including natural killer (NK) cells, T cells, B cells, dendritic cells, and monocytes . The receptor is involved in the regulation of immune responses, particularly in the context of adaptive immunity. It has been shown to modulate B cells and adaptive immunity, thereby influencing susceptibility to autoimmune conditions such as multiple sclerosis .

SLAMF7 is highly expressed in multiple myeloma (MM) cells and is considered a promising target for immunotherapy in this context . The receptor promotes myeloma cell proliferation and growth, making it a critical focus for therapeutic interventions. SLAMF7-CAR T cells, which are T cells modified to express a chimeric antigen receptor targeting SLAMF7, have demonstrated potent antimyeloma reactivity . These modified T cells can effectively eliminate myeloma cells and confer selective fratricide of SLAMF7-positive normal lymphocytes .

The development of SLAMF7-targeted therapies, such as SLAMF7-CAR T cells, represents a significant advancement in the treatment of multiple myeloma. These therapies have shown promise in both preclinical and clinical settings, offering hope for patients with refractory or relapsed myeloma . Additionally, the receptor’s role in modulating immune responses makes it a potential target for other autoimmune and inflammatory conditions .